We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 months, and patients underwent bone marrow aspiration at baseline, and 12 and 24 months of ZOL. Complete DTC response (<4 DTC/mL), serial CTCs, survival, recurrence, and toxicity were determined. Forty-five patients received ZOL. Median baseline DTC was 13.3/mL. Significant reduction in median DTC occurred from baseline to 12 months, and 24 months. Complete DTC response was seen in 32% at 12 months, and 26% at 24 months. Nine patients developed recurrence. Baseline DTC > 30/mL and CTC > 0.8/mL were significantly associated with recurrence and death. Serial reduction in DTCs occurred. Higher baseline DTC > 30/mL and CTC > 0.8/mL correlated with recurrence and death.

我们评估了 I-III 期乳腺癌患者的播散性肿瘤细胞 (DTC) 和循环肿瘤细胞 (CTC)，基线 DTC 大于 4 MM/mL，并接受佐剂唑来膦酸 (ZOL)。ZOL 每 4 周给药一次，持续 24 个月，患者在基线、ZOL 的 12 和 24 个月时接受了骨髓穿刺。确定了完全 DTC 反应 (<4 DTC/mL)、连续 CTC、存活、复发和毒性。45 名患者接受了 ZOL。中位基线 DTC 为 13.3/mL。从基线到 12 个月和 24 个月，中位 DTC 显着减少。12 个月时 32% 和 24 个月时 26% 看到完全 DTC 响应。9 名患者出现复发。基线 DTC > 30/mL 和 CTC > 0.8/mL 与复发和死亡显着相关。DTC 连续减少。